コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
2 by nonreactive serologic tests (rapid plasma reagin and fluorescent treponemal antibody-absorbed), th
5 st for gonorrhea and chlamydia, rapid plasma reagin for syphilis) conducted at baseline, week 26, and
7 % (7.7-11.5) having high-titre (rapid plasma reagin >=1:8) infection, including 16.9% (11.9-24.0%) of
8 stitute for the MHA-TP and that the Spirotek Reagin II test could substitute for the RPR test as a sc
12 reactive test results than with rapid plasma reagin in 2 studies, one with a low-prevalence US popula
13 compared using predicate manual rapid plasma reagin (RPR) and fluorescent treponemal antibody absorpt
15 results were further tested by rapid plasma reagin (RPR) and Treponema pallidum particle agglutinati
16 s, all samples were tested by a rapid plasma reagin (RPR) assay and a treponemal IgM Western blot ass
17 y of 80.7% versus 80.3% for the rapid plasma reagin (RPR) card test (Becton Dickinson Microbiology Sy
18 ed two nontreponemal tests, the rapid plasma Reagin (RPR) card test and the SpiroTek Reagin II test.
20 e cohort of patients with known rapid plasma reagin (RPR) statuses and clinical diagnoses of syphilis
21 e obtained using a quantitative rapid plasma reagin (RPR) test and the Treponema pallidum passive par
22 ed for all episodes of positive rapid plasma reagin (RPR) test results and on a subset with higher RP
23 s serological testing using the rapid plasma reagin (RPR) test with that of the combination of serolo
25 n biologic false-positive (BFP) rapid plasma reagin (RPR) tests among persons infected with human imm
27 nsmission can be assessed using rapid plasma reagin (RPR) tests, reflecting current or recent infecti
28 In multivariate analyses, serum rapid plasma reagin (RPR) titer > or =1 : 32 increased the odds of ne
30 reactors, that is, persons with rapid plasma reagin (RPR) titers > or = 1:4 and negative results for
33 test results: immunoassays and rapid plasma reagin (RPR), respectively, with RPR quantification by e
34 s underwent reflex testing with rapid plasma reagin (RPR), Treponema pallidum particle agglutination
36 munoassay [EIA] reactive and reactive plasma reagin [RPR] nonreactive) are resolved with a second tre
38 treated for high-titer (n=133; rapid plasma reagin [RPR] titer > or = 1:8 and Treponema pallidum hem
39 by a nontreponemal test (i.e., rapid plasma reagin [RPR]) to assess disease activity and treatment s
43 als, 360 (14.4%) had a positive rapid plasma reagin test at screening; 333 (92.5%) had a positive con
44 he search began for the factor, later called reagin, that could mediate an allergy, such as allergic
45 ve syphilis (i.e., women with a rapid plasma reagin titer > or = 1 :8 and a positive Treponema pallid
46 ive status or a decrease in the rapid plasma reagin titer by two or more dilutions at 6 months, refer
47 me 400 mg in achieving a 4-fold rapid plasma reagin titer decrease by 3 or 6 months after treatment.
48 n was higher in patients with a rapid plasma reagin titer of >/=1:8 (97.3%) than in those with a tite
49 ty was higher with higher serum rapid plasma reagin titers (P < .001), and in those treated for uncom
51 ua New Guinea, with high-titre (rapid plasma reagin titre >/=1:8) latent or active yaws, between Apri
53 dum haemagglutination test and rapid plasmin reagin titre of >/=1:8) was higher in cases of yaws (63%
54 ultaneously evaluated using the rapid plasma reagin, Treponema pallidum particle agglutination, and c